Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025Open Access

Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson disease and overlap with other neurodegenerative disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJan HomannASAlexander SmithSMSarah Morgan

Discussion

Loading...

Member takes

Overview

Large-scale proteomics reveals 12 preclinical biomarkers for Parkinson disease in blood samples, suggesting overlaps with other neurodegenerative disorders.

Key Points

  • The study discovered 17 proteins that predict parkinson disease up to 28 years before diagnosis.
  • Replication confirmed 12 key pre-diagnostic biomarkers with strong evidence across multiple cohorts.
  • Cognitive decline was predicted by specific biomarkers, showing potential for earlier intervention.
  • Identified biomarkers shared molecular signatures with Alzheimer's disease and amyotrophic lateral sclerosis, indicating common pathways.

Cite This Study

Homann et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf55ahttps://doi.org/10.1101/2025.07.30.25332433
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leveraging machine learning to predict Parkinson's disease using pre-symptomatic proteomics data.2025
  2. 2Plasma Proteomics for Parkinsons Disease: Diagnostic Classification, Severity Association, and Therapeutic Hypotheses2025
  3. 3Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvement2025 · 3 citations
  4. 4Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.2025
  5. 5Cross-disease LC–MS/MS plasma proteomics identifies reproducible shared and disease-enriched biomarker signatures in neurodegenerative disorders2026